E7389 Versus Capecitabine in Patients With Locally Advanced or Metastatic Breast Cancer Previously Treated With Anthracyclines and Taxanes

Clinical Trial ID NCT00337103

PubWeight™ 10.26^‹?›

🔗 Visit the ClinicalTrials.gov page for NCT00337103

Top papers

Rank	Title	Journal	Year	PubWeight™‹?›
1	Phase III open-label randomized study of eribulin mesylate versus capecitabine in patients with locally advanced or metastatic breast cancer previously treated with an anthracycline and a taxane.	J Clin Oncol	2015	1.85
2	Phase III trials of eribulin mesylate (E7389) in extensively pretreated patients with locally recurrent or metastatic breast cancer.	Clin Breast Cancer	2010	1.41
3	Eribulin mesylate in the treatment of metastatic breast cancer.	Biologics	2012	0.92
4	Health-related quality of life in patients with locally advanced or metastatic breast cancer treated with eribulin mesylate or capecitabine in an open-label randomized phase 3 trial.	Breast Cancer Res Treat	2015	0.88
5	Brain Metastases from Breast Cancer and Response to Treatment with Eribulin: A Case Series.	Breast Cancer (Auckl)	2015	0.82
6	Evolving approaches to metastatic breast cancer patients pre-treated with anthracycline and taxane.	BioDrugs	2013	0.81
7	"New" metastases are associated with a poorer prognosis than growth of pre-existing metastases in patients with metastatic breast cancer treated with chemotherapy.	Breast Cancer Res	2015	0.81
8	Eribulin in Cancer Treatment.	Mar Drugs	2015	0.80
9	Pooled analyses of eribulin in metastatic breast cancer patients with at least one prior chemotherapy.	Ann Oncol	2016	0.78
10	Subgroup Analyses from a Phase 3, Open-Label, Randomized Study of Eribulin Mesylate Versus Capecitabine in Pretreated Patients with Advanced or Metastatic Breast Cancer.	Breast Cancer (Auckl)	2016	0.75
11	Potential clinical applications of halichondrins in breast cancer and other neoplasms.	Breast Cancer (Dove Med Press)	2012	0.75